Altimmune, Inc. (ALT) Stock Analysis and Metrics

Altimmune

NASDAQ: ALT

$2.77 ▼ -0.07 (-2.65%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap346.63 Mn

P/E28.57

Div. Yield0.00

Total Debt (Qtr)34.51 Mn

Add ratio to table…

About

Altimmune, Inc. is a late clinical stage biopharmaceutical company focused on developing novel therapies for serious liver diseases. The firm's lead product candidate is pemvidutide, a peptide engineered to act as a balanced agonist of both glucagon and GLP1 receptors. Pemvidutide originated from the acquisition of Spitfire Pharma in July 2019 and has since been studied in multiple clinical trials. The drug is being evaluated for the treatment of metabolic dysfunction associated steatohepatitis, alcohol use disorder and alcohol associated liver disease. By simultaneously activating glucagon and GLP1 pathways, pemvidutide aims to reduce liver fat, attenuate inflammation, limit fibrosis and promote weight loss while preserving lean muscle mass. Altimmune envisions pemvidutide as a potential first in class therapy that addresses both metabolic and hepatic components of these conditions.

As a pre revenue entity, Altimmune does not generate income from product sales. The company's revenue derives from licensing arrangements, collaborative agreements and possible government or nonprofit grants. Altimmune holds a license agreement with Mederis Diabetes LLC for the EuPort technology platform that underpins pemvidutide's chemical structure. Additionally, the company has entered into a collaboration with Adocia S. A. to develop an oral formulation of pemvidutide aimed at improving patient convenience. Any proceeds from these agreements are modest and are primarily allocated to support ongoing research and development activities. The firm may also seek additional partnership or licensing opportunities to broaden the therapeutic reach of pemvidutide.

Altimmune occupies a specialized niche within the biopharmaceutical sector as a developer of dual glucagon GLP1 receptor agonists that target liver pathology. Its lead candidate pemvidutide is distinguished by a balanced 1:1 activation of glucagon and GLP1 receptors, a pharmacological profile that is uncommon among existing investigational agents. This balanced activity is intended to combine direct hepatocyte effects of glucagon with the appetite regulating and metabolic actions of GLP1. The company has secured Breakthrough Therapy Designation and Fast Track designation from the U. S. Food and Drug Administration for pemvidutide in metabolic dysfunction associated steatohepatitis based on early clinical evidence of substantial improvement over current therapies. These designations may accelerate regulatory review and potentially enable an accelerated approval pathway. Competitors in the metabolic dysfunction associated steatohepatitis arena include Madrigal Pharmaceuticals, Aligos and Viking Therapeutics, which are pursuing thyroid hormone receptor beta selective agonists. Novo Nordisk, Roche and GSK are advancing fibroblast growth factor 21 analogs, while Novo Nordisk also markets a GLP1 agonist. Merck/Hanmi Pharmaceutical and Boehringer Ingelheim are developing GLP1 glucagon dual agonists. Eli Lilly is investigating a GIP GLP1 dual agonist and a GIP GLP1 glucagon triple agonist. Roche is pursuing a GLP1 GIP dual agonist. AstraZeneca is exploring a GLP1 glucagon and amylin combination. Inventiva is working on a pan peroxisome proliferator activated receptor agonist. Sagimet is developing a fatty acid synthetase inhibitor. Apollo Therapeutics Group Limited/HEC Pharma is pursuing a GLP1 FGF21 dual agonist. Pfizer, Roche, Gilead, AstraZeneca and Eli Lilly are also studying small molecule GLP1 agonists. In the alcohol use disorder market, Alkermes markets Vivitrol and generic options such as naltrexone, acamprosate and disulfiram are available. Eli Lilly is developing mazdutide and brenipatide. Smaller entrants such as Adial, Imbrium and Solvonis are active in this space. For alcohol associated liver disease, competitors include GSK with GSK4532990, Novo Nordisk with an FGF21 analog, cagrilintide and semaglutide. Altimmune's competitive advantages stem from the mechanistic balance of pemvidutide, which seeks to simultaneously reduce hepatic lipid accumulation, curb inflammation, limit fibrotic progression and induce weight loss that preferentially spares lean tissue. The Breakthrough Therapy and Fast Track designations may facilitate a swifter regulatory route. Furthermore, a robust patent portfolio protects pemvidutide with expiration dates extending into the 2040s, offering a prolonged period of market exclusivity should the drug reach commercialization.

Altimmune's prospective customers are patients diagnosed with metabolic dysfunction associated steatohepatitis, alcohol use disorder or alcohol associated liver disease. These individuals span a broad demographic that includes adults with obesity, metabolic syndrome and heavy alcohol consumption patterns. Healthcare providers such as hepatologists, gastroenterologists, addiction specialists and primary care physicians would be responsible for prescribing and administering pemvidutide upon approval. Treatment would likely occur in hospitals, outpatient clinics, specialized liver centers and addiction treatment facilities. Insurers, including private health plans and government programs such as Medicare and Medicaid, constitute another critical stakeholder group that influences patient access through coverage and reimbursement decisions. The company has not disclosed specific customer names at this stage, focusing instead on the broader patient and provider populations that could benefit from its therapeutic approach.

Investment Thesis

▲ Bull case

Altimmune’s recent oversubscribed public offering generated $225 million in gross proceeds, pushing pro‑forma cash to roughly $535 million as of April 30 2026. This capital base comfortably funds the company through the anticipated 52‑week data readout of the Phase III MASH PERFORMA trial expected in 2029, removing near‑term financing pressure and allowing management to focus exclusively on trial execution. The strong balance sheet also creates flexibility to pursue nondilutive partnership options for the alcohol use disorder (AUD) program should early data readouts next quarter prove encouraging, thereby preserving equity upside while de‑risking a second major indication. Investors often overlook how this financial cushion translates into operational speed, enabling rapid site activation and enrollment without the typical cash‑flow constraints that slow many mid‑size biotechs. In effect, the market may be underestimating the strategic advantage conferred by a fully funded late‑stage pipeline heading into pivotal readouts.
The PERFORMA Phase III trial incorporates several design features that could accelerate enrollment and improve retention beyond what competitors achieve. A simple titration schedule starting at 1.2 mg and escalating to either 1.8 mg or 2.4 mg after only one or two four‑week steps mirrors the tolerability advantage seen in Phase II, where discontinuation rates were lower than placebo. This patient‑friendly approach is especially relevant in chronic liver disease, where adherence directly influences efficacy outcomes and real‑world effectiveness. By contrast, many GLP‑1‑based regimens require prolonged, multi‑step titration to manage gastrointestinal side effects, leading to higher dropout. The market may not fully appreciate how this tolerability edge could translate into faster enrollment, richer data quality, and a lower risk of trial failure due to non‑adherence.
Pemvidutide’s balanced 1:1 glucagon‑GLP‑1 agonism offers a mechanistic differentiation that addresses both metabolic dysregulation and direct liver pathology, a combination that monotherapy GLP‑1 agents cannot replicate because GLP‑1 receptors are absent in hepatocytes. Preclinical and early clinical signals show rapid reduction in steatosis, inflammation, and early fibrosis, complemented by weight loss that preserves lean muscle mass—a critical factor for the aging MASH population where sarcopenia worsens prognosis. The emerging data from Q‑fibrosis analysis, which isolates true fibrotic change by subtracting steatosis, further supports an early antifibrotic effect at 24 weeks that could resonate with regulators seeking histopathological improvement. Investors may be underestimating the therapeutic breadth of this dual action, which could enable pemvidutide to capture segments of the MASH market that are inadequately served by weight‑loss‑only agents.
Breakthrough Therapy Designation granted by the FDA for pemvidutide in MASH signals a clear regulatory pathway toward accelerated approval, contingent on the 52‑week biopsy endpoint. This designation not only underscores the agency’s confidence in the drug’s potential but also opens doors for more frequent interactions, rolling reviews, and potential priority review vouchers. The company has already aligned its Phase III protocol with both FDA and EMA feedback, indicating that the trial design satisfies key regulatory expectations across major markets. While many peers are still navigating early‑stage discussions, Altimmune’s proactive regulatory engagement could shave months off the approval timeline, a factor that is not yet fully priced into the stock given the distant 2029 readout horizon.
Parallel programs in AUD and ALD provide near‑term catalysts that could re‑rate the stock well before the MASH Phase III readout. Top‑line data from the Phase II RECLAIM trial in AUD are expected next quarter, and management has indicated a preference for nondilutive funding avenues should the data support further development. Additionally, enrollment in the ALD RESTORE trial is slated for completion in Q3 2026, setting the stage for another data readout later this year. Positive outcomes in either indication could validate pemvidutide’s broad liver‑targeting utility, attract partnership interest, and generate revenue streams or milestone payments that would bolster cash reserves beyond the current runway. The market often treats these programs as peripheral, yet they represent concrete, imminent news flow that could shift sentiment.

Altimmune’s recent oversubscribed public offering generated $225 million in gross proceeds, pushing pro‑forma cash to roughly $535 million as of April 30 2026. This capital base comfortably funds the company through the anticipated 52‑week data readout of the Phase III MASH PERFORMA trial expected in 2029, removing near‑term financing pressure and allowing management to focus exclusively on trial execution. The strong balance sheet also creates flexibility to pursue nondilutive partnership options for the alcohol use disorder (AUD) program should early data readouts next quarter prove encouraging, thereby preserving equity upside while de‑risking a second major indication. Investors often overlook how this financial cushion translates into operational speed, enabling rapid site activation and enrollment without the typical cash‑flow constraints that slow many mid‑size biotechs. In effect, the market may be underestimating the strategic advantage conferred by a fully funded late‑stage pipeline heading into pivotal readouts.
The PERFORMA Phase III trial incorporates several design features that could accelerate enrollment and improve retention beyond what competitors achieve. A simple titration schedule starting at 1.2 mg and escalating to either 1.8 mg or 2.4 mg after only one or two four‑week steps mirrors the tolerability advantage seen in Phase II, where discontinuation rates were lower than placebo. This patient‑friendly approach is especially relevant in chronic liver disease, where adherence directly influences efficacy outcomes and real‑world effectiveness. By contrast, many GLP‑1‑based regimens require prolonged, multi‑step titration to manage gastrointestinal side effects, leading to higher dropout. The market may not fully appreciate how this tolerability edge could translate into faster enrollment, richer data quality, and a lower risk of trial failure due to non‑adherence.
Pemvidutide’s balanced 1:1 glucagon‑GLP‑1 agonism offers a mechanistic differentiation that addresses both metabolic dysregulation and direct liver pathology, a combination that monotherapy GLP‑1 agents cannot replicate because GLP‑1 receptors are absent in hepatocytes. Preclinical and early clinical signals show rapid reduction in steatosis, inflammation, and early fibrosis, complemented by weight loss that preserves lean muscle mass—a critical factor for the aging MASH population where sarcopenia worsens prognosis. The emerging data from Q‑fibrosis analysis, which isolates true fibrotic change by subtracting steatosis, further supports an early antifibrotic effect at 24 weeks that could resonate with regulators seeking histopathological improvement. Investors may be underestimating the therapeutic breadth of this dual action, which could enable pemvidutide to capture segments of the MASH market that are inadequately served by weight‑loss‑only agents.
Breakthrough Therapy Designation granted by the FDA for pemvidutide in MASH signals a clear regulatory pathway toward accelerated approval, contingent on the 52‑week biopsy endpoint. This designation not only underscores the agency’s confidence in the drug’s potential but also opens doors for more frequent interactions, rolling reviews, and potential priority review vouchers. The company has already aligned its Phase III protocol with both FDA and EMA feedback, indicating that the trial design satisfies key regulatory expectations across major markets. While many peers are still navigating early‑stage discussions, Altimmune’s proactive regulatory engagement could shave months off the approval timeline, a factor that is not yet fully priced into the stock given the distant 2029 readout horizon.
Parallel programs in AUD and ALD provide near‑term catalysts that could re‑rate the stock well before the MASH Phase III readout. Top‑line data from the Phase II RECLAIM trial in AUD are expected next quarter, and management has indicated a preference for nondilutive funding avenues should the data support further development. Additionally, enrollment in the ALD RESTORE trial is slated for completion in Q3 2026, setting the stage for another data readout later this year. Positive outcomes in either indication could validate pemvidutide’s broad liver‑targeting utility, attract partnership interest, and generate revenue streams or milestone payments that would bolster cash reserves beyond the current runway. The market often treats these programs as peripheral, yet they represent concrete, imminent news flow that could shift sentiment.

▼ Bear case

Despite the strong cash position, Altimmune’s financial runway is tightly coupled to the successful execution of a single, large‑scale Phase III trial in MASH, with no guaranteed revenue streams until at least 2029. Any delay in site activation, patient recruitment, or data readout would directly erode the cash buffer and could necessitate additional financing, potentially on less favorable terms. The company has not disclosed specific contingency plans for scenarios where enrollment lags behind expectations, nor has it quantified the cash burn associated with extending the trial timeline. Investors may be overly optimistic about the sufficiency of current funds, underestimating the financing risk inherent in a binary‑outcome, late‑stage bet.
The competitive landscape for MASH therapeutics is rapidly evolving, with multiple triple‑agonist and novel mechanisms entering late‑stage development. While Altimmune emphasizes its 1:1 glucagon‑GLP‑1 balance, emerging therapies often combine GLP‑1 with additional agonists (e.g., GIP, glucagon) at ratios that may deliver superior metabolic or antifibrotic effects. The management discussion acknowledged the rise of triple agonists but did not detail how pemvidutide would maintain a competitive edge if those agents demonstrate superior fibrosis regression or weight‑loss durability. If competitors achieve comparable or better efficacy with comparable or better tolerability, Altimmune’s differentiation could erode, limiting its market share and pricing power.
Tolerability advantages highlighted in Phase II may not fully translate to the broader, more heterogeneous MASH population expected in Phase III, particularly given the inclusion of patients with advanced fibrosis and comorbid conditions. The trial design relies on a simple titration to mitigate gastrointestinal side effects, yet real‑world use often reveals additional adverse signals such as increased heart rate, blood pressure fluctuations, or glucagon‑mediated metabolic effects that were not prominent in the smaller Phase II cohort. The company did not elaborate on long‑term safety monitoring plans beyond standard adverse event collection, leaving open the possibility that unexpected safety signals could emerge, impacting both regulatory approval and physician uptake.
Regulatory clarity for the AUD indication remains ambiguous, as the FDA has proposed multiple potential endpoints (zero heavy drinking days, change in WHO risk level, or change in heavy drinking days) without a definitive preference. Altimmune’s discussion indicated that the final endpoint will be determined after reviewing Phase II data, but no concrete decision framework was shared. This uncertainty could delay pivotal trial planning, increase development costs, and complicate partner negotiations. Moreover, the looming generic availability of semaglutide‑based agents for obesity and potentially AUD could undercut pricing power before Altimmune secures a differentiated position, a risk that was not directly addressed in the call.
Although the company plans to evaluate an auto‑injector for launch, the current Phase III protocol utilizes manual injection, raising questions about the alignment between clinical trial data and the eventual delivery system. Transitioning to an auto‑injector post‑approval will require bridging studies to demonstrate comparable pharmacokinetics and user acceptability, adding time and cost to the commercialization timeline. Management noted that a separate comparability study will be performed but did not specify its size, timeline, or potential outcomes. Any discrepancy between the manual‑injection efficacy observed in Phase III and the auto‑injector performance could impede market adoption, a factor that is not reflected in the current valuation.

Despite the strong cash position, Altimmune’s financial runway is tightly coupled to the successful execution of a single, large‑scale Phase III trial in MASH, with no guaranteed revenue streams until at least 2029. Any delay in site activation, patient recruitment, or data readout would directly erode the cash buffer and could necessitate additional financing, potentially on less favorable terms. The company has not disclosed specific contingency plans for scenarios where enrollment lags behind expectations, nor has it quantified the cash burn associated with extending the trial timeline. Investors may be overly optimistic about the sufficiency of current funds, underestimating the financing risk inherent in a binary‑outcome, late‑stage bet.
The competitive landscape for MASH therapeutics is rapidly evolving, with multiple triple‑agonist and novel mechanisms entering late‑stage development. While Altimmune emphasizes its 1:1 glucagon‑GLP‑1 balance, emerging therapies often combine GLP‑1 with additional agonists (e.g., GIP, glucagon) at ratios that may deliver superior metabolic or antifibrotic effects. The management discussion acknowledged the rise of triple agonists but did not detail how pemvidutide would maintain a competitive edge if those agents demonstrate superior fibrosis regression or weight‑loss durability. If competitors achieve comparable or better efficacy with comparable or better tolerability, Altimmune’s differentiation could erode, limiting its market share and pricing power.
Tolerability advantages highlighted in Phase II may not fully translate to the broader, more heterogeneous MASH population expected in Phase III, particularly given the inclusion of patients with advanced fibrosis and comorbid conditions. The trial design relies on a simple titration to mitigate gastrointestinal side effects, yet real‑world use often reveals additional adverse signals such as increased heart rate, blood pressure fluctuations, or glucagon‑mediated metabolic effects that were not prominent in the smaller Phase II cohort. The company did not elaborate on long‑term safety monitoring plans beyond standard adverse event collection, leaving open the possibility that unexpected safety signals could emerge, impacting both regulatory approval and physician uptake.
Regulatory clarity for the AUD indication remains ambiguous, as the FDA has proposed multiple potential endpoints (zero heavy drinking days, change in WHO risk level, or change in heavy drinking days) without a definitive preference. Altimmune’s discussion indicated that the final endpoint will be determined after reviewing Phase II data, but no concrete decision framework was shared. This uncertainty could delay pivotal trial planning, increase development costs, and complicate partner negotiations. Moreover, the looming generic availability of semaglutide‑based agents for obesity and potentially AUD could undercut pricing power before Altimmune secures a differentiated position, a risk that was not directly addressed in the call.
Although the company plans to evaluate an auto‑injector for launch, the current Phase III protocol utilizes manual injection, raising questions about the alignment between clinical trial data and the eventual delivery system. Transitioning to an auto‑injector post‑approval will require bridging studies to demonstrate comparable pharmacokinetics and user acceptability, adding time and cost to the commercialization timeline. Management noted that a separate comparability study will be performed but did not specify its size, timeline, or potential outcomes. Any discrepancy between the manual‑injection efficacy observed in Phase III and the auto‑injector performance could impede market adoption, a factor that is not reflected in the current valuation.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Type Of Arrangement Breakdown of Revenue (2020)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Type Of Arrangement Breakdown of Revenue (2020)

Peer Comparison

Create an account

Sign In

Reset Password